WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318985
CAS#: 129-06-6 (sodium)
Description: Warfarin is an anticoagulant normally used in the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body, respectively. It was initially introduced in 1948 as a pesticide against rats and mice, and is still used for this purpose, although more potent poisons such as brodifacoum have since been developed. In the early 1950s, warfarin was found to be effective and relatively safe for preventing thrombosis and thromboembolism in many disorders. It was approved for use as a medication in 1954, and has remained popular ever since. Warfarin is the most widely prescribed oral anticoagulant drug in North America.
Hodoodo Cat#: H318985
Name: Warfarin sodium
CAS#: 129-06-6 (sodium)
Chemical Formula: C19H15NaO4
Exact Mass: 0.00
Molecular Weight: 330.315
Elemental Analysis: C, 69.09; H, 4.58; Na, 6.96; O, 19.37
Related CAS #: 129-06-6 (sodium) 81-81-2 (free acid) 2610-86-8 (potassium)
Synonym: Warfarin sodium, Coumadin, Aldocumar, Tedicumar, Warfant, Marevan
IUPAC/Chemical Name: sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate
InChi Key: KYITYFHKDODNCQ-UHFFFAOYSA-M
InChi Code: InChI=1S/C19H16O4.Na/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22;/h2-10,15,21H,11H2,1H3;/q;+1/p-1
SMILES Code: CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+]
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 129-06-6 (sodium salt); 81-81-2 (free acid).
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 330.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Atoui M, Gunda S, Lakkireddy D. Left atrial appendage closure is preferred to chronic warfarin therapy: the pro perspective. Card Electrophysiol Clin. 2015 Sep;7(3):403-13. doi: 10.1016/j.ccep.2015.05.019. Epub 2015 Jul 10. Review. PubMed PMID: 26304519.
2: Tian L, Zhang J, Xiao S, Huang J, Zhang Y, Shen J. Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis. Meta Gene. 2015 Jun 5;5:43-54. doi: 10.1016/j.mgene.2015.05.003. eCollection 2015 Sep. Review. PubMed PMID: 26106580; PubMed Central PMCID: PMC4473094.
3: Entezari-Maleki T, Dousti S, Hamishehkar H, Gholami K. A systematic review on comparing 2 common models for management of warfarin therapy; pharmacist-led service versus usual medical care. J Clin Pharmacol. 2015 Jun 22. doi: 10.1002/jcph.576. [Epub ahead of print] Review. PubMed PMID: 26100092.
4: Rubboli A, Agewall S, Huber K, Lip GY. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. Int J Cardiol. 2015 Oct 1;196:133-8. doi: 10.1016/j.ijcard.2015.06.006. Epub 2015 Jun 15. Review. PubMed PMID: 26093527.
5: Wagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015 May;135(5):e1333-6. doi: 10.1542/peds.2014-2578. Review. PubMed PMID: 25917992.
6: Hanley CM, Kowey PR. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis. 2015 Feb;7(2):165-71. doi: 10.3978/j.issn.2072-1439.2015.01.23. Review. PubMed PMID: 25713732; PubMed Central PMCID: PMC4321074.
7: Watanabe H, Itoh H, Tsuchiya Y, Miyagi N, Sugiyama T, Nakai Y, Shinozaki Y, Noguchi T, Jinbu Y, Kusama M. [Reinforcement of warfarin action in a patient administered S-1]. Gan To Kagaku Ryoho. 2015 Jan;42(1):131-3. Review. Japanese. PubMed PMID: 25596696.
8: Arepally GM, Ortel TL. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annu Rev Med. 2015;66:241-53. doi: 10.1146/annurev-med-051113-024633. Review. PubMed PMID: 25587651.
9: Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014 Nov 25;130(22):e191-3. doi: 10.1161/CIRCULATIONAHA.114.010426. Review. PubMed PMID: 25421049.
10: Dzeshka MS, Lip GY. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. Expert Opin Drug Saf. 2015 Jan;14(1):45-62. doi: 10.1517/14740338.2015.973847. Epub 2014 Oct 24. Review. PubMed PMID: 25341529.
11: Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015 Jan;25(1):33-41. doi: 10.1016/j.tcm.2014.09.001. Epub 2014 Sep 6. Review. PubMed PMID: 25282448; PubMed Central PMCID: PMC4278947.
12: Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther. 2014 Dec;39(6):628-36. doi: 10.1111/jcpt.12207. Epub 2014 Sep 24. Review. PubMed PMID: 25252149.
13: Milić N, Milosević N, Golocorbin Kon S, Bozić T, Abenavoli L, Borrelli F. Warfarin interactions with medicinal herbs. Nat Prod Commun. 2014 Aug;9(8):1211-6. Review. PubMed PMID: 25233607.
14: McGuinn TL, Scherr S. Anticoagulation clinic versus a traditional warfarin management model. Nurse Pract. 2014 Oct 15;39(10):40-6. doi: 10.1097/01.NPR.0000451803.29453.0c. Review. PubMed PMID: 25225978.
15: Frei J, Carroll VS. Oral anticoagulants: the move beyond warfarin. J Neurosci Nurs. 2014 Oct;46(5):253-5. doi: 10.1097/JNN.0000000000000085. Review. PubMed PMID: 25188682.
16: Borkowski AA, Kardani A, Mastorides SM, Thomas LB. Warfarin pharmacogenomics: recommendations with available patented clinical technologies. Recent Pat Biotechnol. 2014;8(2):110-5. Review. PubMed PMID: 25185986.
17: Yang Y, Liu T, Zhao J, Li G. Warfarin-related nephropathy: prevalence, risk factors and prognosis. Int J Cardiol. 2014 Oct 20;176(3):1297-8. doi: 10.1016/j.ijcard.2014.07.166. Epub 2014 Aug 11. Review. PubMed PMID: 25127970.
18: Su D, Wang K, Qin S, Pang Y. Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease: a meta-analysis. Cardiology. 2014;129(1):55-64. doi: 10.1159/000363732. Epub 2014 Aug 12. Review. PubMed PMID: 25116427.
19: Crowl A, Schullo-Feulner A, Moon JY. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother. 2014 Nov;48(11):1479-83. doi: 10.1177/1060028014546361. Epub 2014 Aug 7. Review. PubMed PMID: 25104566.
20: Turagam MK, Velagapudi P, Bongu NR, Kocheril AG. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. Cardiovasc Hematol Disord Drug Targets. 2014;14(1):79-86. Review. PubMed PMID: 25088126.
